German Tech Holding GmbH & Co. KGaA
by Investor Relations
Public disclosure of inside information according to article 17 MAR Frankfurt/Main (pta/22.10.2026/23:35) - Frankfurt/Main, 22 October 2026 – The general partner of German Tech Holding GmbH & Co. KGaA (GTH) sets the final subscription price of the ongoing public offer for the subscription of treasury shares at 0.07 euros per share, as, in the Company's assessment, many of its shareholders are waiting until the end of the subscription period, which runs for a further five days, to decide on the exercise of their subscription rights. Only shareholders of GTH have the opportunity to subscribe for GTH shares at this subscription price. In the share purchase applications received so far, the full exercise of subscription rights without a price limit within the subscription price range was predominantly specified, i.e. the subscription rights were exercised in full up to a subscription price of 0.21 euros. Subscription rights are not exercised automatically. GTH shareholders who wish to exercise their subscription rights at the subscription price, which is less than half of today's Xetra closing price, and thereby, among other things, participate undiminished, to the extent of their previous stake in the Company, in GTH's life sciences/biotech prospects through the intended investment in Zirnostics, must do so proactively and, for this purpose, complete a share purchase application and submit it to the Company by 27 October 2026. The form is available for download at https://germantechholding.com/index.php/for-shareholders/the-share/. Insofar as not all shareholders exercise their subscription rights in full, the remaining GTH shareholders may apply for oversubscription. This enables GTH shareholders to increase their shareholding quota beyond their previous stake. However, there is no entitlement to acceptance of an oversubscription application. GG Beteiligungen UG (GGB) has undertaken to acquire, at the subscription price set, all shares that are acquired by GTH shareholders neither within the scope of their subscription rights nor by way of oversubscription. In the allocation, oversubscription applications take precedence over this backstop order of GGB. The full placement is thus secured, and an acquisition of shares from the subscription offer by third parties is not possible. How many shares GGB will take over will only be determined after the end of the subscription period on 27 October 2026, as purchase applications may be submitted to the Company by GTH shareholders until then. Christoph Gerlinger, CEO and founder of GTH, holds an indirect interest of just under 50 % in GG Beteiligungen UG. For further information, the Investor Q&A is available to shareholders on the GTH homepage. About German Tech Holding German Tech Holding (GTH) is an investment company founded in 2012 and based in Frankfurt am Main. During its active years as a leading German venture capital provider under the name German Startups Group, GTH held stakes with great success in, among others, Chrono24, Delivery Hero, Fiagon, Mister Spex, Remerge and Scalable Capital. To this day it holds investments including AuctionTech, SoundCloud and Thinksurance. Through its SaaS-based white-label solution PropNow for digital bidding and offer processes in the real estate market, AuctionTech is the European market leader. GTH pursues opportunities in the fields of artificial intelligence and life sciences/biotech. Cognicare AI, a spin-off from GTH's investment in the company builder Softmax AI, addresses the structurally growing market for senior care facilities with highly sought-after AI applications. In the field of life science, GTH is examining an investment opportunity in Zirnostics GmbH that has presented itself and has signed a term sheet in this regard. Zirnostics is preparing a clinical trial for the approval of its disruptive tracer for PSMA-PET/CT imaging in prostate cancer, which is up to 100-fold superior to legacy tracers in terms of tumour-to-background contrast and has already been successfully clinically tested for years in several hundred patients. Securities ID number A1MMEV ISIN DE000A1MMEV4 Symbol GTH Further information: germantechholding.com ( http://germantechholding.com/) Investor Relations Contact Rosenberg Strategic Communications Mario Groß MC Services AG Fotini Vogiatzi Important notice The information document pursuant to Annex IX of Regulation (EU) 2017/1129 and the share purchase application are exclusively authoritative for the currently ongoing public offer. This announcement constitutes neither investment advice nor an investment recommendation. This announcement constitutes neither an offer to purchase or subscribe for securities nor investment advice or an investment recommendation. Disclaimer This publication is advertising. It constitutes neither an offer to sell nor a solicitation to purchase or subscribe for securities in any jurisdiction, in particular not in the United States of America. An investment decision may be made exclusively on the basis of the information document prepared by the issuer pursuant to Article 1 (4) subpara. 1 lit. db) of the Prospectus Regulation and in accordance with the requirements set out in Annex IX of the Prospectus Regulation, which is published at http://www.germantechholding.com under the heading "For Shareholders" ( https://germantechholding.com/index.php/for-shareholders/the-share/) and has been filed with the Federal Financial Supervisory Authority ("BaFin"). BaFin, as the competent national authority, has neither reviewed nor approved this document. Potential investors should read the information document before making an investment decision in order to fully understand the potential risks and opportunities of the decision to invest in the securities. This publication is not intended, either directly or indirectly, for distribution or dissemination into or within the United States of America (including its territories and possessions, any state of the United States or the District of Columbia) or to publications with a general circulation in the United States of America. The securities are not and will not be registered under the provisions of the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may be sold or offered for purchase in the United States of America only with prior registration under the provisions of the Securities Act as currently in force or, without prior registration, only on the basis of an exemption. The issuer does not intend to register the offer of securities in whole or in part in the United States of America or to conduct a public offering in the United States of America. Outside Germany, this publication is directed only at, and is intended exclusively for, those persons in member states of the EEA who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation ("qualified investors"). In addition, in the United Kingdom this publication is distributed only to, and is directed only at, those qualified investors (i) who have professional experience in matters relating to investments within the meaning of Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (ii) who are high net worth companies within the meaning of Article 49(2)(a) to (d) of the Order, or (iii) who are other persons to whom this publication may lawfully be communicated. This publication is not an offer to purchase securities in Canada, Japan or Australia. (end) emitter: German Tech Holding GmbH & Co. KGaA address: Humboldtstraße 60B, 60318 Frankfurt am Main country: Germany contact person: Investor Relations phone: +49 69 348690520 e-mail: ir@germantechholding.com website: germantechholding.com ISIN(s): DE000A1MMEV4 (share) stock exchanges: free market in Dusseldorf, scale in Frankfurt, free market in Munich, free market in Stuttgart; open market in Tradegate BSX pressetext Nachrichtenagentur GmbH Ad-hoc and financial news distributed by pressetext.adhoc. Archive: http://adhoc.pressetext.com The emitter is responsible for the content. Contact: adhoc@pressetext.com or +43-1-81140-0.
